Protagonist Therapeutics, Inc.
PTGX
Rang in Aktien
#2295
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Aktienkurs
$134.37
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$8.70B
Veränderung (1 Tag)
4.37%
Veränderung (1 Jahr)
75.15%
Land
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategorie
Healthcare
Dividendenrendite-Verlauf für Protagonist Therapeutics, Inc. (PTGX)
Dividendenrendite (TTM) von Protagonist Therapeutics, Inc. (Aktienkürzel: PTGX) zum 2023-12-31: 0.00%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Protagonist Therapeutics, Inc. (PTGX) von 2014 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
| Jahr | Dividendenrendite | ändert |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | Dividendenrendite | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
